Skip to content


Evox has assembled an experienced, multidisciplinary team with deep and broad expertise spanning all aspects from early research and development to intellectual property and commercialisation of novel drug modalities. We believe in creating an open and transparent environment where we foster and leverage collaboration and innovation while having a singular focus on our mission to improve the lives of patients suffering from severe diseases.

Dr Antonin de Fougerolles

Chief Executive Officer

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage including Moderna, Alnylam, and Ablynx.

Dr Per Lundin

Co-Founder and Chief Business Officer

Per has over 15 years of experience in advising, founding and leading biotech companies developing ground breaking therapies. Prior to co-founding Evox in 2016, he founded and led a cell therapy company, practiced patent law as a European Patent Attorney and worked in business development and consulting.

Kerry Jaycock

VP People & Culture

Kerry has over 15 years’ experience in Human Resources across a variety of different industry sectors and organisational sizes. Her expertise is in organisational development, transformation and change with a focus on culture and employee engagement. Prior to joining Evox, Kerry was Head of Human Resources at Immunocore.

Dr David Lowe

VP Research

David has over 20 years of biotech and large pharma R&D experience in advancing protein and antibody-based therapeutics as well as exploring novel therapeutic modalities such as gene therapy, mRNA therapeutics and exosomes. Prior to his joining Evox, David spent over 12 years at Astra Zeneca (AZ), most recently as Senior Director in charge of Biologics Engineering.

Dr Sonya Montgomery

Chief Medical Officer

Sonya is a physician with over 20 years’ experience of clinical development, advancing therapeutic programmes from first in human studies through to registration. Sonya has held leadership positions most recently at Gyroscope Therapeutics and ProQR and has global development experience with Pfizer and Relypsa based in the United States.

Peter Jones


Peter has more than 30 years of process development experience in the biopharmaceutical industry, including cell and gene therapies. During those years, he was involved in bringing more than 16 products to commercialization. Prior to his joining Evox, Peter spent time at Autolus, Oxford Biomedica, GlaxoSmithKline, and Genzyme.